12:00 AM
Sep 08, 2014
 |  BioCentury  |  Emerging Company Profile

Biscayne: Antagonizing cancer

Biscayne's GHRH antagonist for cancer could be first in class

Biscayne Pharmaceuticals Inc. is developing peptide antagonists that target three different cancer growth pathways and could provide an alternative for prostate cancer patients who have become insensitive to hormone-based therapies. The company plans to enter the clinic by early 2016 with a potential first-in-class candidate targeting the GHRH receptor.

"Almost all of the therapies today for prostate cancer focus on hormone deprivation or the role of the androgen receptor and androgen deprivation. But patients eventually become insensitive to these therapies," said Samuel Reich, co-founder and CEO of Biscayne.

For example, Zytiga abiraterone from Johnson & Johnson targets androgen hormone production, while Xtandi enzalutamide from Medivation Inc. and Astellas Pharma Inc. targets the binding of the androgen to its receptor.

Additionally, Xtandi, Zytiga and Xofigo radium-223 from Bayer AG only address single pathways through which tumors like prostate cancer proliferate and metastasize. Xofigo is a radiotherapy that exerts its activity via a calcium-dependent pathway in bone metastases in prostate cancer patients.


Read the full 826 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >